Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

ISS recommends one of Sarissa's three nominees for Alkermes board

Published 06/20/2023, 09:32 AM
Updated 06/20/2023, 11:32 AM
© Reuters.
BIIB
-
ALKS
-

By Svea Herbst-Bayliss

NEW YORK (Reuters) - Proxy advisory firm Institutional Investor Services urged Alkermes (NASDAQ:ALKS) shareholders to elect one of three director candidates proposed by activist hedge fund Sarissa Capital, arguing more outside pressure on management is needed right now.

ISS said Sarah Schlesinger, a physician with experience serving on public company boards, should be elected to Alkermes' 11-member board at next week's annual meeting. She should replace board member Richard Gaynor, a physician who serves as president of BioNTech US, the report said.

"A dissident nominee is needed on the board to add urgency and pressure on management to change," ISS wrote in the report, adding "shareholders' interests would be best served by adding a direct shareholder representative to the board."

ISS however did not back Sarissa's two other nominees, including the hedge fund's co-founder Alex Denner.

Alkermes said Schlesinger, who has been nominated by Denner to sit on other boards, is not independent of the hedge fund.

ISS praised Alkermes, valued at $5.3 billion, for having refreshed its board with new directors several times over the last years and for its success in developing and bringing new drugs to market. But it criticized the company's costs, saying SG&A spending as a percent of sales has been higher than rivals and has been growing.

Sarissa, which owns 8.45% of Alkermes, has challenged the company before. In 2021, the hedge fund and Alkermes reached an agreement to add a new director. Last year Sarissa dropped a board challenge, and this year it nominated three candidates.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

This year's campaign is drawing outsized attention because of Denner's moves. Last week, he abruptly stepped down from the Biogen (NASDAQ:BIIB) board, possibly to avoid a conflict of interest between the two companies which have a commercial relationship.

But ISS wrote it recommended against Denner because a conflict still exists after Biogen recommended his seat be filled by Susan Langer, who has been identified by Biogen as Denner's romantic partner.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.